Latham & Watkins Advises Mineralys Therapeutics in its US$40 Million Series A Funding Round

A San Diego-based team advised the clinical-stage biopharmaceutical company in the financing.

April 07, 2021

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific, has announced that the Company completed a US$40 million Series A funding round. The financing was led by HBM Healthcare Investments and Samsara BioCapital with founding investment firm Catalys Pacific and Adam Street Partners participating in the round. The company also announced that the US Food and Drug Administration has accepted their Investigational New Drug Application for an investigational compound MLS-101, an aldosterone synthase inhibitor, for the treatment of hypertension. The financing will enable Mineralys to complete its Phase 2 proof-of-concept study for MLS-101, as well as preparatory work for its pivotal trial development program.

Latham & Watkins LLP represented Mineralys Therapeutics, Inc. in the financing with a San Diego-based deal team led by partner Cheston Larson and counsel Chris Geissinger, with associate Evan Youngstrom.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.